211096-49-0 Usage
Uses
Used in Pharmaceutical Industry:
GSK-CXCR2 is used as an anti-tumor pharmaceutical for its potential role in modulating the tumor microenvironment and reducing inflammation associated with cancer progression. By targeting CXCR2, it may help to disrupt the recruitment and activation of immune cells that support tumor growth and metastasis.
Additionally, GSK-CXCR2 may be used as a therapeutic agent for other inflammatory conditions, given its ability to inhibit the CXCR2 receptor and potentially reduce the inflammatory response. This could have applications in treating a range of diseases where excessive inflammation contributes to pathology, such as autoimmune disorders and chronic inflammatory conditions.
Biological Activity
Potent CXCR2 antagonist that inhibits CINC-1-mediated but not C5a-mediated Ca 2+ mobilization (IC 50 values are 3.4 and 6800 nM respectively). Inhibits CINC-induced chemotaxis and attenuates neutrophil accumulation in inflammatory lung injury in vivo .
Biochem/physiol Actions
SB265610 is a potent and selective CXCR2 chemokine receptor antagonist. It has a Kd = 2.5 nM.
Check Digit Verification of cas no
The CAS Registry Mumber 211096-49-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,1,0,9 and 6 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 211096-49:
(8*2)+(7*1)+(6*1)+(5*0)+(4*9)+(3*6)+(2*4)+(1*9)=100
100 % 10 = 0
So 211096-49-0 is a valid CAS Registry Number.
211096-49-0Relevant articles and documents
IL-8 receptor antagonists
-
, (2008/06/13)
This invention relates to novel benzo-2-triazole substituted compounds, pharmaceutical compositions, processes for their preparation, and use thereof in treating IL-8, GROα, GROβ, GROγ and NAP-2 mediated diseases.
